

Ella Zomer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7178006/publications.pdf>

Version: 2024-02-01

91
papers

2,048
citations

304368

22
h-index

301761

39
g-index

92
all docs

92
docs citations

92
times ranked

2782
citing authors

#	ARTICLE	IF	CITATIONS
1	Global Incidence of Frailty and Prefrailty Among Community-Dwelling Older Adults. <i>JAMA Network Open</i> , 2019, 2, e198398.	2.8	289
2	The projected burden of primary total knee and hip replacement for osteoarthritis in Australia to the year 2030. <i>BMC Musculoskeletal Disorders</i> , 2019, 20, 90.	0.8	248
3	Recent Patterns of Multimorbidity Among Older Adults in High-Income Countries. <i>Population Health Management</i> , 2019, 22, 127-137.	0.8	120
4	Adherence and Persistence Among Statin Users Aged 65 Years and Over: A Systematic Review and Meta-analysis. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2018, 73, 813-819.	1.7	63
5	Productivity Burden of Hypertension in Australia. <i>Hypertension</i> , 2019, 73, 777-784.	1.3	58
6	The Productivity Burden of Diabetes at a Population Level. <i>Diabetes Care</i> , 2018, 41, 979-984.	4.3	57
7	Effect of Comorbidity Assessed by the Charlson Comorbidity Index on the Length of Stay, Costs and Mortality among Older Adults Hospitalised for Acute Stroke. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 2532.	1.2	48
8	A Systematic Review and Meta-analysis of the Factors Associated With Nonadherence and Discontinuation of Statins Among People Aged ≥65 Years. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2018, 73, 798-805.	1.7	46
9	The effectiveness and cost effectiveness of dark chocolate consumption as prevention therapy in people at high risk of cardiovascular disease: best case scenario analysis using a Markov model. <i>BMJ</i> , 2012, 344, e3657-e3657.	3.0	39
10	Overview of pharmacoeconomic modelling methods. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 944-950.	1.1	35
11	Cost-effectiveness of dapagliflozin in chronic heart failure: an analysis from the Australian healthcare perspective. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 975-982.	0.8	35
12	Productivity burden of smoking in Australia: a life table modelling study. <i>Tobacco Control</i> , 2019, 28, 297-304.	1.8	33
13	Patterns of statin use and long-term adherence and persistence among older adults with diabetes. <i>Journal of Diabetes</i> , 2018, 10, 699-707.	0.8	32
14	Predictors of first-year nonadherence and discontinuation of statins among older adults: a retrospective cohort study. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 227-235.	1.1	32
15	The impact of diabetes on productivity in China. <i>Diabetologia</i> , 2019, 62, 1195-1203.	2.9	31
16	Validation of two Framingham cardiovascular risk prediction algorithms in an Australian population: the "old"™ versus the "new"™ Framingham equation. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2011, 18, 115-120.	3.1	30
17	The costs of epilepsy in Australia. <i>Neurology</i> , 2020, 95, e3221-e3231.	1.5	28
18	Novel Treatment Strategies for Secondary Prevention of Cardiovascular Disease: A Systematic Review of Cost-Effectiveness. <i>Pharmacoeconomics</i> , 2020, 38, 1095-1113.	1.7	28

#	ARTICLE	IF	CITATIONS
19	Natural Regression of Frailty Among Community-Dwelling Older Adults: A Systematic Review and Meta-Analysis. <i>Gerontologist</i> , The, 2020, 60, e286-e298.	2.3	26
20	A 10-Year Trend in Statin Use Among Older Adults in Australia: an Analysis Using National Pharmacy Claims Data. <i>Cardiovascular Drugs and Therapy</i> , 2018, 32, 265-272.	1.3	24
21	Cost-effectiveness of rivaroxaban and aspirin compared to aspirin alone in patients with stable cardiovascular disease: An Australian perspective. <i>International Journal of Cardiology</i> , 2018, 270, 54-59.	0.8	24
22	The cost-effectiveness of PCSK9 inhibitors - The Australian healthcare perspective. <i>International Journal of Cardiology</i> , 2018, 267, 183-187.	0.8	23
23	Cost-Effectiveness of Renal Denervation Therapy for Treatment-Resistant Hypertension: A Best Case Scenario. <i>American Journal of Hypertension</i> , 2018, 31, 1156-1163.	1.0	23
24	Cost of gastroenteritis in Australia: A healthcare perspective. <i>PLoS ONE</i> , 2018, 13, e0195759.	1.1	22
25	The cost-effectiveness of icosapent ethyl in combination with statin therapy compared with statin alone for cardiovascular risk reduction. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 897-904.	0.8	21
26	Productivity-Adjusted Life-Years: A New Metric for Quantifying Disease Burden. <i>Pharmacoeconomics</i> , 2021, 39, 271-273.	1.7	21
27	Future burden of cardiovascular disease in Australia: impact on health and economic outcomes between 2020 and 2029. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1212-1219.	0.8	21
28	Cost-effectiveness of health technologies in adults with type 1 diabetes: a systematic review and narrative synthesis. <i>Systematic Reviews</i> , 2020, 9, 171.	2.5	20
29	Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness Analysis. <i>Pharmacoeconomics</i> , 2020, 38, 1007-1020.	1.7	20
30	Economic evaluation of clinical quality registries: a systematic review. <i>BMJ Open</i> , 2019, 9, e030984.	0.8	19
31	Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with peripheral or carotid artery disease: An Australian healthcare perspective. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 858-868.	0.8	19
32	Impact of tobacco use on health and work productivity in Malaysia. <i>Tobacco Control</i> , 2020, 29, 111-117.	1.8	19
33	Cost-Effectiveness Analysis of a Hybrid Closed-Loop System Versus Multiple Daily Injections and Capillary Glucose Testing for Adults with Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2020, 22, 812-821.	2.4	19
34	Switching, Discontinuation, and Reinitiation of Statins Among Older Adults. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2675-2677.	1.2	18
35	The impact of diabetes on the productivity and economy of Bangladesh. <i>BMJ Global Health</i> , 2020, 5, e002420.	2.0	18
36	Evaluating the clinical and cost effectiveness of a behaviour change intervention for lowering cardiovascular disease risk for people with severe mental illnesses in primary care (PRIMROSE study): study protocol for a cluster randomised controlled trial. <i>Trials</i> , 2016, 17, 80.	0.7	17

#	ARTICLE	IF	CITATIONS
37	Prevalence and impact of non-cardiovascular comorbidities among older adults hospitalized for non-ST segment elevation acute coronary syndrome. <i>Cardiovascular Diagnosis and Therapy</i> , 2019, 9, 250-261.	0.7	17
38	Measures of Population Ageing in Australia from 1950 to 2050. <i>Journal of Population Ageing</i> , 2018, 11, 367-385.	0.8	16
39	Sacubitril-valsartan versus enalapril for acute decompensated heart failure: a cost-effectiveness analysis. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 966-972.	0.8	16
40	Health and productivity burden of coronary heart disease in the working Indonesian population using life-table modelling. <i>BMJ Open</i> , 2020, 10, e039221.	0.8	14
41	Switching, Persistence and Adherence to Statin Therapy: a Retrospective Cohort Study Using the Australian National Pharmacy Data. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 867-877.	1.3	14
42	Cardiovascular risk prediction in a population with the metabolic syndrome: Framingham vs. UKPDS algorithms. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 384-390.	0.8	13
43	Effectiveness and cost-effectiveness of a cardiovascular risk prediction algorithm for people with severe mental illness (PRIMROSE). <i>BMJ Open</i> , 2017, 7, e018181.	0.8	13
44	Could low birth weight and preterm birth be associated with significant burden of hip osteoarthritis? A systematic review. <i>Arthritis Research and Therapy</i> , 2018, 20, 121.	1.6	13
45	The cost-effectiveness of canakinumab for secondary prevention of cardiovascular disease: The Australian healthcare perspective. <i>International Journal of Cardiology</i> , 2019, 285, 1-5.	0.8	13
46	Bempedoic acid for high-risk patients with CVD as adjunct lipid-lowering therapy: A cost-effectiveness analysis. <i>Journal of Clinical Lipidology</i> , 2020, 14, 772-783.	0.6	13
47	Self-sampling kits to increase HIV testing among black Africans in the UK: the HAUS mixed-methods study. <i>Health Technology Assessment</i> , 2018, 22, 1-158.	1.3	13
48	Cost-effectiveness of meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine in Australian adolescents. <i>Vaccine</i> , 2019, 37, 5009-5015.	1.7	12
49	Prevalence and Incidence of Statin Use and 3-Year Adherence and Discontinuation Rates Among Older Adults With Dementia. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2018, 33, 527-534.	0.9	11
50	The economic impact of familial hypercholesterolemia on productivity. <i>Journal of Clinical Lipidology</i> , 2020, 14, 799-806.e3.	0.6	11
51	The Health and Productivity Burden of Depression in South Korea. <i>Applied Health Economics and Health Policy</i> , 2021, 19, 941-951.	1.0	11
52	The impact of coronary heart disease prevention on work productivity: a 10-year analysis. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 418-425.	0.8	11
53	Cost-Effectiveness Analysis of Non-Statin Lipid-Modifying Agents for Secondary Cardiovascular Disease Prevention Among Statin-Treated Patients in Thailand. <i>Pharmacoeconomics</i> , 2019, 37, 1277-1286.	1.7	10
54	The Health and Productivity Burden of Migraines in Australia. <i>Headache</i> , 2020, 60, 2291-2303.	1.8	10

#	ARTICLE	IF	CITATIONS
55	Attainment of Low-Density Lipoprotein Cholesterol Goals in Statin Treated Patients: Real-World Evidence From Australia. <i>Current Problems in Cardiology</i> , 2022, 47, 101068.	1.1	10
56	Effectiveness and cost-effectiveness of interventions that cause weight loss and reduce the risk of cardiovascular disease. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 118-124.	2.2	9
57	Cost-Effectiveness of Switching Patients With Heart Failure and Reduced Ejection Fraction to Sacubitril/Valsartan: The Australian Perspective. <i>Heart Lung and Circulation</i> , 2020, 29, 1310-1317.	0.2	9
58	Cost Burden and Cost-Effective Analysis of the Nationwide Implementation of the Quality in Acute Stroke Care Protocol in Australia. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2021, 30, 105931.	0.7	9
59	Productivity Benefits of Preventing Type 2 Diabetes in Australia: A 10-Year Analysis. <i>Diabetes Care</i> , 2021, 44, 715-721.	4.3	9
60	Outcomes and Excess Costs among Patients with Cardiovascular Disease. <i>Heart Lung and Circulation</i> , 2013, 22, 724-730.	0.2	8
61	Cost-effectiveness of Radial Access Percutaneous Coronary Intervention in Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2021, 156, 44-51.	0.7	8
62	Estimating the economic impacts of percutaneous coronary intervention in Australia: a registry-based cost burden study. <i>BMJ Open</i> , 2021, 11, e053305.	0.8	8
63	The Cost of Control: Cost-effectiveness Analysis of Hybrid Closed-Loop Therapy in Youth. <i>Diabetes Care</i> , 2022, 45, 1971-1980.	4.3	8
64	Predicting the Impact of Polypill Use in a Metabolic Syndrome Population: An Effectiveness and Cost-Effectiveness Analysis. <i>American Journal of Cardiovascular Drugs</i> , 2013, 13, 121-128.	1.0	7
65	Predictors of statin use among older adults: A nationwide cross-sectional study. <i>Journal of Clinical Lipidology</i> , 2019, 13, 156-162.e1.	0.6	7
66	Urotensin II in chronic liver disease: <i>In vivo</i> effect on vascular tone. <i>Scandinavian Journal of Gastroenterology</i> , 2008, 43, 103-109.	0.6	6
67	Predictors of health care use among patients with or at high risk of atherothrombotic disease: Two-year follow-up data. <i>International Journal of Cardiology</i> , 2014, 175, 72-77.	0.8	6
68	An Economic Evaluation of the All New Zealand Acute Coronary Syndrome Quality Improvement Registry Program (ANZACS-QI 28). <i>Heart Lung and Circulation</i> , 2020, 29, 1046-1053.	0.2	6
69	The Preventable Productivity Burden of Kidney Disease in Australia. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 938-949.	3.0	6
70	Trends in the utilisation of lipid-lowering medications in Australia: an analysis of national pharmacy claims data. <i>Current Problems in Cardiology</i> , 2021, , 100880.	1.1	6
71	Primary care management of cardiovascular risk for people with severe mental illnesses: the Primrose research programme including cluster RCT. <i>Programme Grants for Applied Research</i> , 2019, 7, 1-98.	0.4	6
72	Assessing the impact of smoking on the health and productivity of the working-age Indonesian population using modelling. <i>BMJ Open</i> , 2020, 10, e041832.	0.8	6

#	ARTICLE	IF	CITATIONS
73	Productivity burden of hypertension in Japan. <i>Hypertension Research</i> , 2021, 44, 1524-1533.	1.5	5
74	The Cost-Effectiveness of Supplemental Carnosine in Type 2 Diabetes. <i>Nutrients</i> , 2022, 14, 215.	1.7	5
75	Characterising experiences with acute myeloid leukaemia using an Instagram content analysis. <i>PLoS ONE</i> , 2021, 16, e0250641.	1.1	4
76	Patterns and Predictors of Adherence to Statin Therapy Among Older Patients: Protocol for a Systematic Review. <i>JMIR Research Protocols</i> , 2017, 6, e39.	0.5	4
77	The cost-effectiveness of radial access percutaneous coronary intervention: A propensity-score matched analysis of Victorian data. <i>Clinical Cardiology</i> , 2022, 45, 435-446.	0.7	4
78	Estimating the benefits of obesity prevention on productivity: an Australian perspective. <i>International Journal of Obesity</i> , 2022, 46, 1463-1469.	1.6	4
79	Attainment of low-density lipoprotein cholesterol goals in patients treated with combination therapy: A retrospective cohort study in primary care. <i>Journal of Clinical Lipidology</i> , 2022, 16, 498-507.	0.6	4
80	Statins for people at low risk of cardiovascular disease. <i>Lancet</i> , The, 2012, 380, 1817.	6.3	3
81	Can oral vitamin D prevent the cardiovascular diseases among migrants in Australia? Provider perspective using Markov modelling. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2015, 42, 596-601.	0.9	3
82	Patterns of Medication Dispensation for Multiple Comorbidities among Older Adults in Australia. <i>Pharmacy (Basel, Switzerland)</i> , 2018, 6, 134.	0.6	3
83	"If I don't work, I don't get paid": An Australian qualitative exploration of the financial impacts of acute myeloid leukaemia. <i>Health and Social Care in the Community</i> , 2022, 30, .	0.7	3
84	Estimating the Productivity Impact of Acute Myeloid Leukemia in Australia Between 2020 and 2029, Using a Novel Work Utility Measure: The Productivity-Adjusted Life Year (PALY). <i>JCO Oncology Practice</i> , 2021, 17, e1803-e1810.	1.4	2
85	The Impact of Diabetes on Productivity in India. <i>Diabetes Care</i> , 2021, 44, 2714-2722.	4.3	2
86	Do patients with haematological malignancies suffer financial burden? A cross-sectional study of patients seeking care through a publicly funded healthcare system. <i>Leukemia Research</i> , 2022, 112, 106748.	0.4	2
87	Projected New-Onset Cardiovascular Disease by Socioeconomic Group in Australia. <i>Pharmacoeconomics</i> , 2022, , 1.	1.7	2
88	Dynamics of switching, adherence, and persistence of dipeptidyl peptidase-4 inhibitors use: A nationwide cohort study. <i>Diabetes Research and Clinical Practice</i> , 2019, 158, 107909.	1.1	1
89	Assessing the impact of smoking on the health and productivity of the working-age Indonesian population using modelling. <i>BMJ Open</i> , 2020, 10, e041832.	0.8	1
90	It doesn't stop at validation: patient reported outcome measures require ongoing and iterative development. <i>Supportive Care in Cancer</i> , 2022, 30, 995-998.	1.0	0

#	ARTICLE	IF	CITATIONS
91	An economic evaluation of the All New Zealand Acute Coronary Syndrome Quality Improvement Registry programme-subanalyses for Māori (ANZACS-QI 42). New Zealand Medical Journal, 2020, 133, 16-32.	0.5	0